- NuCana plc announced the publication of new data from the NuTide:303 clinical study of NUC-3373 in combination with pembrolizumab, along with complementary preclinical findings, on **October 14, 2025**.  **[1709626_0001193125-25-238219_d88344d6k.htm:0]** **[1709626_0001193125-25-238219_d88344dex991.htm:0]** 
- The study demonstrated a favorable efficacy and safety profile for NUC-3373 plus pembrolizumab in heavily pre-treated patients with advanced solid tumors.  **[1709626_0001193125-25-238219_d88344dex991.htm:0]** 
- Key clinical findings include a patient with metastatic melanoma remaining **progression-free at 23 months** with a durable partial response, and a patient with urothelial carcinoma of the bladder achieving a **100% reduction in tumor lesion size** and staying on treatment for over 15 months.  **[1709626_0001193125-25-238219_d88344dex991.htm:0]** **[1709626_0001193125-25-238219_d88344dex991.htm:1]** 
- Preclinical data supports these findings, showing NUC-3373 promotes the release of immunogenic damage-associated molecular patterns (DAMPs), enhances activation of natural killer (NK) cells, and, in combination with a PD-1 inhibitor, enhances tumor cell death.  **[1709626_0001193125-25-238219_d88344dex991.htm:1]** 
- NuCana anticipates maintaining its **cash runway into 2029**.  **[1709626_0001193125-25-238219_d88344dex991.htm:1]**

NuCana (NCNA)